Subtopic Deep Dive
Lipoprotein Lipase in Atherosclerosis
Research Guide
What is Lipoprotein Lipase in Atherosclerosis?
Lipoprotein lipase (LPL) is the rate-limiting enzyme for hydrolysis of triglycerides in chylomicrons and VLDL, with dysregulated activity contributing to remnant lipoprotein accumulation and atherosclerosis plaque formation.
LPL deficiency elevates triglyceride-rich lipoproteins, promoting atherogenic remnants as described in postprandial atherogenesis models (Zilversmit, 1979, 1703 citations). Functional variants influence lipoprotein phenotypes linked to coronary heart disease risk (Austin et al., 1990, 1416 citations). Over 50 papers explore LPL's role in metabolic syndrome and dyslipidemia within lipid metabolism disorders.
Why It Matters
LPL modulation affects postprandial lipemia and subendothelial lipoprotein retention, key initiators of atherosclerosis (Zilversmit, 1979; Tabas et al., 2007). In obesity-related dyslipidemia, reduced LPL activity drives atherogenic phenotypes treatable via fibrates or lifestyle interventions (Klop et al., 2013). Therapeutic targeting of LPL variants could reduce cardiovascular events in metabolic syndrome patients (Grundy et al., 2005; Berglund et al., 2012).
Key Research Challenges
Quantifying LPL Activity Variants
Genetic and post-translational regulation of LPL variants complicates assessment of atherogenic risk (Austin et al., 1990). Measuring functional LPL in vivo requires advanced imaging and enzymatic assays not standardized across studies. Over 20 papers highlight inconsistent phenotyping in hypertriglyceridemia guidelines (Berglund et al., 2012).
Postprandial Remnant Dynamics
Postprandial chylomicron remnants evade LPL hydrolysis, driving plaque formation, but human models are limited (Zilversmit, 1979). Capturing transient lipemia challenges clinical trial design in obesity cohorts (Klop et al., 2013). Few studies integrate real-time lipoprotein tracking with atherosclerosis imaging.
LPL's Dual Atherogenic Role
LPL protects via triglyceride clearance but promotes retention when overexpressed in endothelium (Tabas et al., 2007). Balancing deficiency versus excess effects hinders drug development. Metabolic syndrome guidelines note unresolved paradoxes in LPL therapeutics (Grundy et al., 2005).
Essential Papers
Diagnosis and Management of the Metabolic Syndrome
Scott M. Grundy, James I. Cleeman, Stephen R. Daniels et al. · 2005 · Circulation · 11.6K citations
The metabolic syndrome has received increased attention in the past few years. This statement from the American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) is ...
Atherogenesis: a postprandial phenomenon.
D.B. Zilversmit · 1979 · Circulation · 1.7K citations
The hypothesis that plasma chylomicrons in persons who ingest a cholesterol-rich diet are atherogenic is evaluated. Evidence is presented that in humans, and experimental animals, chylomicron remna...
Dyslipidemia in Obesity: Mechanisms and Potential Targets
Boudewijn Klop, J ELTE, Manuel Castro Cabezas · 2013 · Nutrients · 1.6K citations
Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and bot...
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.
M A Austin, Mary‐Claire King, K M Vranizan et al. · 1990 · Circulation · 1.4K citations
In a community-based study of 301 subjects from 61 nuclear families, two distinct phenotypes (denoted A and B) were identified by nondenaturing gradient gel electrophoretic analysis of low density ...
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
David Højland Ipsen, Jens Lykkesfeldt, Pernille Tveden‐Nyborg · 2018 · Cellular and Molecular Life Sciences · 1.4K citations
Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis
Ira Tabas, Kevin Jon Williams, Jan Borén · 2007 · Circulation · 1.4K citations
The key initiating process in atherogenesis is the subendothelial retention of apolipoprotein B–containing lipoproteins. Local biological responses to these retained lipoproteins, including a chron...
Metabolic Syndrome
Paresh Dandona, Ahmad Aljada, Ajay Chaudhuri et al. · 2005 · Circulation · 1.3K citations
Reading Guide
Foundational Papers
Start with Zilversmit (1979) for postprandial remnant hypothesis, Austin et al. (1990) for genetic phenotypes, and Tabas et al. (2007) for retention mechanisms—these establish LPL-atherosclerosis causality with over 4,000 combined citations.
Recent Advances
Study Klop et al. (2013) on obesity dyslipidemia targets and Berglund et al. (2012) guidelines for hypertriglyceridemia management to contextualize LPL therapeutics.
Core Methods
Core techniques: gradient gel electrophoresis for LDL subclasses (Austin et al., 1990); enzymatic assays and genetic sequencing for LPL variants; postprandial fat-loading tests (Zilversmit, 1979).
How PapersFlow Helps You Research Lipoprotein Lipase in Atherosclerosis
Discover & Search
Research Agent uses searchPapers and exaSearch to retrieve 50+ papers on LPL variants, then citationGraph maps connections from Zilversmit (1979) to modern dyslipidemia studies, while findSimilarPapers expands from Austin et al. (1990) to uncover hidden remnant-focused works.
Analyze & Verify
Analysis Agent employs readPaperContent on Tabas et al. (2007) for subendothelial retention mechanisms, verifies LPL activity claims via verifyResponse (CoVe) against Grundy et al. (2005), and runs PythonAnalysis with pandas to meta-analyze triglyceride levels across 20 hypertriglyceridemia papers, graded by GRADE for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in LPL therapeutic trials via contradiction flagging between Klop et al. (2013) and Berglund et al. (2012), then Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to draft review sections with exportMermaid diagrams of lipoprotein pathways.
Use Cases
"Meta-analyze LPL activity correlations with plaque burden from imaging studies."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas correlation on extracted triglyceride/plaque data from 15 papers) → statistical output with p-values and GRADE scores.
"Draft LaTeX figure of LPL hydrolysis pathway in atherosclerosis."
Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure + latexSyncCitations (Zilversmit 1979, Tabas 2007) + latexCompile → compiled PDF with cited diagram.
"Find code for simulating postprandial LPL kinetics."
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → validated Python script for remnant accumulation models.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ LPL-atherosclerosis papers: searchPapers → citationGraph → DeepScan 7-step analysis with CoVe checkpoints → structured report on variants. Theorizer generates hypotheses on LPL inhibitors from Klop et al. (2013) and Berglund et al. (2012), chaining gap detection to exportMermaid models. DeepScan verifies postprandial claims across Zilversmit (1979) descendants.
Frequently Asked Questions
What defines LPL's role in atherosclerosis?
LPL hydrolyzes triglycerides in remnants; impaired activity causes subendothelial retention initiating plaques (Tabas et al., 2007; Zilversmit, 1979).
What methods study LPL dysfunction?
Nondenaturing gel electrophoresis identifies atherogenic phenotypes (Austin et al., 1990); fasting/postprandial triglyceride assays guide diagnosis (Berglund et al., 2012).
What are key papers on LPL and atherosclerosis?
Foundational: Zilversmit (1979, postprandial remnants, 1703 citations), Austin et al. (1990, phenotypes, 1416 citations), Tabas et al. (2007, retention, 1361 citations).
What open problems exist in LPL research?
Resolving LPL's context-dependent atheroprotective vs. pro-atherogenic effects; developing isoform-specific inhibitors beyond fibrates (Klop et al., 2013; Grundy et al., 2005).
Research Lipid metabolism and disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lipoprotein Lipase in Atherosclerosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lipid metabolism and disorders Research Guide